Karyopharm Therapeutics (KPTI) Corporate presentation summary

Strategic highlights and pipeline developments

• 2026 marks a transformative year with major Phase 3 readouts and a strengthened shareholder foundation.

• XPOVIO (selinexor) is approved in over 50 countries and targets multiple cancer indications, including myelofibrosis and endometrial cancer.

• Topline Phase 3 SENTRY trial data in myelofibrosis reported in March 2026 showed an encouraging profile; additional Phase 3 data in endometrial cancer expected mid-2026.

• U.S. myelofibrosis market opportunity is multi-billion dollar, with potential for selinexor plus ruxolitinib to reach ~$1B in annual net sales at peak.

• Commercial organization is positioned for targeted launches, leveraging deep hematological oncology expertise.

Myelofibrosis clinical results and commercial opportunity

• SENTRY Phase 3 trial: selinexor plus ruxolitinib achieved superior SVR35 rates (50% vs. 28%) at week 24, with rapid and sustained spleen volume reduction.

• Similar symptom improvement to ruxolitinib alone; promising overall survival signal with >50% reduction in risk of death (HR 0.43, p=0.0222).

• VAF reduction suggests potential disease modification; manageable safety profile consistent with known agents.

• Significant unmet need: two-thirds of patients do not achieve SVR35 with current standard of care.

• Commercial launch strategy targets both academic and community settings, covering 100% of key accounts.

Endometrial cancer program

• Phase 3 XPORT-EC-042 trial focuses on TP53 wild-type endometrial cancer, a population with no approved targeted maintenance therapies.

• SIENDO trial subgroup analysis showed median PFS benefit of 28.4 months for selinexor vs. 5.2 months for placebo in TP53 wild-type patients.

• Safety profile in endometrial cancer consistent with known selinexor effects; most common adverse events include nausea, vomiting, and thrombocytopenia.

• U.S. addressable market for TP53 wild-type endometrial cancer estimated at ~6,000+ patients annually.

• Topline data from XPORT-EC-042 anticipated mid-2026.